← Back to Search

Chemotherapy

Chemotherapy + Radiation for Oropharyngeal Cancer (ARTHOUSE Trial)

Phase 2
Recruiting
Led By Michelle Mierzwa
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >18
AJCC 8 Stage III (cT4 or N3)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years from start of treatment
Awards & highlights

Summary

This trial wants to understand more about patients with a type of throat cancer caused by the HPV virus. They want to identify the patients who are at the highest risk of the cancer coming back after treatment.

Who is the study for?
This trial is for adults over 18 with advanced HPV-related squamous cell carcinoma of the oropharynx, specifically stage III (cT4 or N3). Participants must be in good physical condition (ECOG 0-1), have certain blood and liver function levels within normal ranges, and be able to receive chemotherapy. Women who can bear children and men must use effective birth control during the study.Check my eligibility
What is being tested?
The study is testing whether using detailed imaging techniques like DCE MRI and FDG-PET to guide radiation therapy can improve outcomes for high-risk throat cancer patients while maintaining or reducing treatment side effects compared to standard therapies.See study design
What are the potential side effects?
Potential side effects include those commonly associated with radiation therapy such as skin irritation, fatigue, dry mouth, difficulty swallowing, and nausea. Chemotherapy may cause additional risks like hair loss, anemia, increased infection risk due to low white blood cell counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18.
Select...
My cancer is at an advanced stage but has not spread to distant organs.
Select...
My throat cancer is advanced, p16 positive, and I am referred for chemo and radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years from start of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years from start of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Toxicity of treatment based off of Adverse Events collected per CTCAE v5.0
Secondary outcome measures
Biomarker analysis from tumor tissue, to compile biomarker information
Local regional recurrence free survival
MRIs and FDG PET scans- efficacy and toxicity
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment2 Interventions
Patients will initially receive a single prescription of 70 Gy to PTVhigh in 35 fractions with RT given once daily, 5 days a week along with weekly platinum (standard therapy). All fields must be treated daily. On days when chemotherapy is given, it will be administered prior to RT. Prescription to high risk PTV will be 70Gy in 35 fractions and to PTV2 will be 56Gy in 35 fractions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation
2003
Completed Phase 2
~780

Find a Location

Who is running the clinical trial?

University of Michigan Rogel Cancer CenterLead Sponsor
295 Previous Clinical Trials
24,270 Total Patients Enrolled
Michelle MierzwaPrincipal InvestigatorUniversity of Michigan Rogel Cancer Center
~13 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top